7 results about "H1n1 virus" patented technology

The invention discloses a preparation method and application of an aptamer functionalized nano-enzyme probe for detecting H1N1 virus, and belongs to the technical field of biosensing and virus detection. The invention aims to solve the problem of limitation of the existing H1N1 virus detection method in sensitivity, specificity and stability. The preparation method comprises the following steps: 1, mixing and incubating a three-metal nickel-palladium-gold nano-enzyme solution containing a hollow structure and a sulfhydrylation H1N1 hemagglutinin protein specific recognition aptamer solution; and 2, sealing the surface. According to the application, the kit is used for detecting the H1N1 virus.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to preparation and application of beta-, gamma-or delta-aminoketone derivatives, the structure of the derivatives is shown as a general formula (I), in the formula, R1 is alkyl, aryl and the like; r2 represents an aryl group, a heteroaryl group, an alkynyl group, an alkenyl group, a cyano group or the like; r3 is hydrogen, alkyl, aryl or the like; r4 represents an aryl sulfonyl group, a heteroaryl sulfonyl group, an alkyl sulfonyl group, a sulfonate group or the like; in the structural formula, n represents the length of a carbon chain, and the value is 0-2. The derivative is novel in structure, has good antiviral activity, particularly has a good inhibition effect on H1N1 virus, and has great application potential in the aspect of antiviral effect; meanwhile, the preparation method has the advantages of few reaction steps, no need of metal catalysis, no need of complex substrate preparation, simplicity and safety in operation, mild reaction conditions, low cost, higher atom economy and high yield.

The invention provides application of levistilide A in preparation of anti-influenza virus drugs, and belongs to the technical field of biological medicines. The influenza virus is an H1N1 virus. In-vitro anti-influenza experiments find that levistilide A can significantly inhibit infection of H1N1 virus and significantly improve cytopathy caused by influenza virus infection. The H1N1 virus half inhibitory concentration (IC50) of the levistilide A in MDCK cells is 1.462 M, and the H1N1 virus half inhibitory concentration (IC50) of the levistilide A in A549 cells is 0.455 M. The invention proves that the levistilactone A has a remarkable anti-H1NA virus effect, can be used for preparing the anti-influenza virus medicine, and has an excellent application prospect.

The invention discloses a CRISPR-Cas12a system H1N1 virus hypersensitive nucleic acid detection system and a kit and application thereof, the CRISPR-Cas12a system H1N1 virus hypersensitive nucleic acid detection system comprises a Cas12a recognition system, an allosteric regulation component, a signal amplification component and a report system, the system reduces background noise through allosteric inhibition, improves sensitivity through dual signal amplification, and realizes hypersensitive detection of an H1N1 virus M1 gene in combination with ErCas12a protease. The method has the advantages of low detection lower limit, no dependence on natural PAM sequence, less than 1 hour of time consumption and the like, and the sensitivity and the specificity are superior to those of the existing RT-qPCR detection method. By adjusting crRNA and probe sequences, the platform disclosed by the invention can be expanded for portable rapid detection of various respiratory pathogens, and is particularly suitable for primary medical treatment and field emergency screening.

FIELD: biotechnology.SUBSTANCE: plasmid DNA matrix pVAX-C3-H1-PolyA and the polynucleotide mRNA vaccine synthesized using the said DNA matrix pVAX-C3-H1-PolyA, encoding the hemagglutinin of the influenza A / H1N1 virus and ensuring its expression and induction of a specific immune response when introduced into the body of mammals, used in immunology, genetic engineering, biotechnology and medicine. A recombinant plasmid DNA matrix pVAX-C3-H1-PolyA was obtained, providing expression of mRNA in mammalian cells, having the nucleotide sequence SEQ ID NO: 1 with a size of 4849 bp, a molecular weight of 3.1 MDa and including a fragment of 1680 bp, having coordinates from 699 to 2378 bp and containing an artificial gene encoding the hemagglutinin protein of the influenza A / Wisconsin / 67 / 2022 (H1N1)pdm09 virus without the transmembrane and cytoplasmic domain with the addition of the trimerizing domain of phage T4 with the initiation codon ATG. An mRNA vaccine was obtained having the nucleotide sequence SEQ ID NO: 2, obtained using a DNA matrix and containing an open reading frame encoding the amino acid sequence SEQ ID NO:3 of the influenza virus hemagglutinin immunogen protein, and ensuring the synthesis and secretion of the said protein in the body of mammals.EFFECT: expansion of the range of more relevant mRNA vaccines against the influenza virus.2 cl, 6 dwg, 3 ex

The application discloses THK01 and derivatives thereof, a preparation method and application of the THK01 and the derivatives in preparation of anti-inflammatory drugs, and relates to the following steps: a series of chemical reactions, including Wittig reaction, Diels-Alder reaction, Cadogan reaction, Fischer indole synthesis reaction, demethylation reaction, reduction reaction and click chemistry reaction, are carried out on ortho-nitrobenzaldehyde containing specific substituents, so that THK01 structural modification derivatives with different substituents are obtained. The THK01 structural modification derivatives are synthesized in various routes, and the reaction success rate is high. In vitro and in vivo experiments show that the compounds can significantly inhibit the production of NO and inflammatory reactions at a low concentration, and can effectively treat inflammatory bowel disease and H1N1 virus-induced acute pneumonia in an animal model. The findings provide valuable candidate compounds and new treatment strategies for developing new, safe and efficient anti-inflammatory drugs.

The application provides a flavone glycoside with antiviral activity and a preparation method and application thereof. The structural formula of the flavone compound phloretin 3'-C-(2-O-trans-p-coumaroyl-3-O-beta-D-glucosyl)-beta-D-fucosyl-6'-O-(2-O-beta-D-fucosyl)-alpha-L-arabinofuranoside of the application is shown as formula (I), and the compound is isolated from dried or fresh products of fruits, stems or leaves of Averrhoa carambola. In vitro pharmacological experiments prove that the compound phloretin 3'-C-(2-O-trans-p-coumaroyl-3-O-beta-D-glucosyl)-beta-D-fucosyl-6'-O-(2-O-beta-D-fucosyl)-alpha-L-arabinofuranoside has good anti-H1N1 virus ability, and the EC 50 value thereof is 8.916 muM, indicating that the compound has good antiviral activity. The flavone compound phloretin 3'-C-(2-O-trans-p-coumaroyl-3-O-beta-D-glucosyl)-beta-D-fucosyl-6'-O-(2-O-beta-D-fucosyl)-alpha-L-arabinofuranoside is expected to be used as a lead compound to develop a new antiviral drug.